Pfizer sues Sanofi-Aventis over Exubera marketing deal

At least one of three co-marketing deals struck up before the
merger of Sanofi-Synthelabo and Aventis has turned out to be a thorn in the newly formed pharma's side.
Pfizer has filed lawsuits in the U.S. and Germany against Sanofi-Aventis for a ruling to enforce the "change-of-control" clause in the co-marketing agreement between the companies
for the inhaled insulin, Exubera.
Neither company was willing to answer whether Pfizer is seeking to
enforce the change- in-control clause to buy back sole rights to Exubera or force a Sanofi-Aventis buyout of the rights.
Calls to a Sanofi-Aventis spokeswoman requesting comment on the
lawsuit were referred to Pfizer. A spokesman for Pfizer said his company is seeking a judgment to support its view that the Sanofi-Aventis merger constituted a change-in-control as defined by the 1998 Exubera co-marketing agreement between
the companies.
In other co-marketing deals made before the merger, Sanofi-Aventis
has agreed on the terms of the copromotion deal with Procter &
Gamble for the osteoporosis drug Actonel, and will also retain the
rights to Altana's in-development asthma therapy Alvesco.
"We have a co-development and co-promotion agreement with
Aventis for the U.S.," said an Alvesco spokeswoman. "Once reaching the market, Sanofi-Aventis will book all U.S. sales of Alvesco and Altana will receive royalties on these sales.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions